BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
BillionToOne (NASDAQ:BLLN) announced that management will participate in the William Blair 46th Annual Growth Stock Conference.
Rhea-AI Summary
BillionToOne (NASDAQ:BLLN) announced that management will participate in the William Blair 46th Annual Growth Stock Conference. The company will present from 12:40pm to 1:10pm CT on Tuesday, June 2, 2026.
A live and archived webcast will be available on the Events & Presentations page of BillionToOne’s investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BLLN
In the May 28 session, BLLN gained 7.45%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- June 2, 2026
- William Blair 46th Annual Growth Stock Conference presentation date
- Presentation time window
- 12:40pm–1:10pm Central Time
- Scheduled slot for company presentation at conference
Historical Context
-
Q1 2026 beat with revenue $108.4M and guidance raised to $450M–$465M.
-
Launch of Unity Confirm non‑invasive confirmation test with 16/16 concordance data.
-
Announcement of timing and webcast details for Q1 2026 earnings release.
-
Appointment of VP Medical Affairs & Clinical Development, Oncology, and CMO transition.
-
Very strong Q4/FY2025 results, raised 2026 outlook to $430M–$445M and positive GAAP outlook.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.
Management will present from 12:40pm to 1:10pm Central Time on Tuesday, June 2, 2026.
A live and archived webcast will be available on the “Events & Presentations” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/news-events/events-presentations.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
Investor Contact
ir@billiontoone.com
Media Contact
billiontoone@moxiegrouppr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.